

# Chronic Kidney Disease Drugs Market - 2021-2031

<https://marketpublishers.com/r/C7B49603B9F9EN.html>

Date: November 2025

Pages: 200

Price: US\$ 2,999.00 (Single User License)

ID: C7B49603B9F9EN

## Abstracts

The Chronic Kidney Disease Drugs Market was valued at US\$ 10,923.29 million in 2021 and is anticipated to reach US\$ 19,427.41 million by 2031, at a CAGR of 0.066 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Chronic Kidney Disease Drugs Market.

This report delivers a comprehensive overview of the Chronic Kidney Disease Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Chronic Kidney Disease Drugs Market. The Chronic Kidney Disease Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2021–2031.

Chronic Kidney Disease Drugs Market Scope:

By Drug Class

Calcium Channel Blockers

ACE Inhibitors

## B- Blockers

Diuretics

Erythropoiesis-Stimulating Agents (ESAS)

Others

## By Route of Administration

Oral

Subcutaneous

Intravenous

## By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

## Key Players

Pfizer Inc.

Sanofi S.A.

F. Hoffmann-La Roche Ltd.

Teva Pharmaceutical Industries Ltd.

AstraZeneca Plc.

Kissei Pharmaceutical Co

AbbVie Inc.

GlaxoSmithKline Plc

Amgen Inc.

Akebia Therapeutics(LIST NOT EXHAUSTIVE)

## Major Highlights

This report delivers a comprehensive overview of the Chronic Kidney Disease Drugs Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Chronic Kidney Disease Drugs Market. The Chronic Kidney Disease Drugs Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2021–2031.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

## Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

## Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

## Why Choose DataM?

**Data-Driven Insights:** Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

**Post-Purchase Support and Expert Analyst Consultations:** As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

**White Papers and Case Studies:** Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

**Annual Updates on Purchased Reports:** As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

**Specialized Focus on Emerging Markets:** DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than

offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

**Value of DataM Reports:** Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

### Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

## Contents

### **1. MARKET METHODOLOGY AND SCOPE**

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

### **2. MARKET DEFINITION AND OVERVIEW**

### **3. EXECUTIVE SUMMARY**

### **4. MARKET DYNAMICS**

- 4.1. Market Impacting Factors
  - 4.1.1. Drivers
    - 4.1.1.1. The rising requirement for chronic kidney disease drugs
    - 4.1.1.2. Increasing technological advancements
  - 4.1.2. Restraints:
    - 4.1.2.1. High cost of chronic kidney disease drugs
    - 4.1.2.2. Risk associated with CKD drugs
  - 4.1.3. Opportunity
  - 4.1.4. Impact Analysis

### **5. INDUSTRY ANALYSIS**

- 5.1. Porter's Five Forces
- 5.2. Unmet Needs
- 5.3. Epidemiology
- 5.4. Supply chain Analysis
- 5.5. Regulatory Analysis

### **6. COVID-19 ANALYSIS**

- 6.1. Analysis of Covid-19 on the Market
  - 6.1.1. Before COVID-19 Market Scenario
  - 6.1.2. Present COVID-19 Market Scenario
  - 6.1.3. After COVID-19 or Future Scenario
- 6.2. Pricing Dynamics Amid Covid-19
- 6.3. Demand-Supply Spectrum

6.4. Government Initiatives Related to the Market During the Pandemic

6.5. Manufacturer's Strategic Initiatives

6.6. Conclusion

## **7. BY DRUG CLASS**

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

7.1.2. Market Attractiveness Index, By Drug Class

7.2. Calcium Channel Blockers\*

7.2.1. Introduction

7.2.2. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029

7.3. ACE Inhibitors

7.4. B- Blockers

7.5. Diuretics

7.6. Erythropoiesis-Stimulating Agents (ESAS)

7.7. Others

## **8. BY ROUTE OF ADMINISTRATION**

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

8.1.2. Market Attractiveness Index, By Route of Administration

8.2. Oral\*

8.2.1. Introduction

8.2.2. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029

8.3. Subcutaneous

8.4. Intravenous

## **9. BY DISTRIBUTION CHANNEL**

9.1. Introduction

9.1.1. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Distribution Channel

9.1.2. Market Attractiveness Index, By Distribution Channel

9.2. Hospital Pharmacies\*

9.2.1. Introduction

9.2.2. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029

9.3. Retail Pharmacies

9.4. Online Pharmacies

9.5. Others

## **10. BY REGION**

10.1. Introduction

10.1.1. Market Size Analysis, US\$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region

10.1.2. Market Attractiveness Index, By Region

10.2. North America

10.2.1. Introduction

10.2.2. Key Region-Specific Dynamics

10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel

10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.2.6.1. The U.S.

10.2.6.2. Canada

10.2.6.3. Mexico

10.3. Europe

10.3.1. Introduction

10.3.2. Key Region-Specific Dynamics

10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class

10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel

10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.3.6.1. Germany

10.3.6.2. The U.K.

10.3.6.3. France

10.3.6.4. Italy

10.3.6.5. Spain

10.3.6.6. Rest of Europe

10.4. South America

- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
- 10.5. Asia Pacific
  - 10.5.1. Introduction
  - 10.5.2. Key Region-Specific Dynamics
  - 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  - 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  - 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
  - 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    - 10.5.6.1. China
    - 10.5.6.2. India
    - 10.5.6.3. Japan
    - 10.5.6.4. Australia
    - 10.5.6.5. Rest of Asia Pacific
- 10.6. Middle East and Africa
  - 10.6.1. Introduction
  - 10.6.2. Key Region-Specific Dynamics
  - 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  - 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  - 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), Distribution Channel
  - 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

## **11. COMPETITIVE LANDSCAPE**

- 11.1. Key Developments and Strategies
- 11.2. Company Share Analysis
- 11.3. Product Benchmarking
- 11.4. List of Key Companies to Watch

## **12. COMPANY PROFILES**

### 12.1. Pfizer Inc.

12.1.1. Company Overview

12.1.2. Product Portfolio and Description

12.1.3. Key Highlights

12.1.4. Financial Overview

### 12.2. Sanofi S.A.

### 12.3. F. Hoffmann-La Roche Ltd.

### 12.4. Teva Pharmaceutical Industries Ltd.

### 12.5. AstraZeneca Plc.

### 12.6. Kissei Pharmaceutical Co

### 12.7. AbbVie Inc.

### 12.8. GlaxoSmithKline Plc

### 12.9. Amgen Inc.

### 12.10. Akebia Therapeutics(\*LIST NOT EXHAUSTIVE)

## **13. DATAM INTELLIGENCE**

### 13.1. Appendix

### 13.2. About Us and Services

### 13.3. Contact Us

## I would like to order

Product name: Chronic Kidney Disease Drugs Market - 2021-2031

Product link: <https://marketpublishers.com/r/C7B49603B9F9EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C7B49603B9F9EN.html>